Scandinavian Biolabs, the Copenhagen-based innovator in the haircare industry, closed a €4 million investment round led by Auréa Group.WHO: Founded in 2020, Scandinavian Biolabs has established itself as a leader in science-backed, non-invasive, preventative products targeting early-stage hair loss. The brand's hero product, the clinically tested Bio-Pilixin Activation Serum, has been a game-changer in the market. Scandinavian Biolabs launched as a direct-to-consumer (DTC) brand, rapidly building a loyal customer and leveraging this success to expand into retail and pharmacies across multiple geographies. WHY: The €4 million cash infusion from Auréa will enable Scandinavian Biolabs to pursue its ambitious growth plans more aggressively, forging a leadership position in the UK, Germany, and the Nordics, while also entering the US market, scaling the business through an online offering, and expanding strategic retail such as pharmacies.IN THEIR OWN WORDS: Niels Konradi, COO and co-founder of Scandinavian Biolabs: “What started as a personal battle with hair loss has grown into something far bigger. It’s been incredible to see how many lives we’ve touched with our products. I am particularly excited about the potential to offer even more value to our customers.”Anders Reckendorff, CEO and co-founder of Scandinavian Biolabs: “We’ve built a strong foundation with our innovative products and proven that if we can provide our customers value and results, we will also have a strong business. We are excited to be joined by our new investors who can help us leapfrog our growth through their experience and know-how.